Video Lectures

The video lectures below are provided as an educational opportunity and resource for laboratory professionals. “Current video lectures” provide FREE continuing education credits when viewed in their entirety and upon the completion of a quiz with a score of 80 percent or higher.

Video Lecture CME/SAM PACE Florida
Update on HPV Testing by Robert Schlaberg, MD, Dr Med, MPH
Number of Credits: 0.75

This talk will provide an overview of the biology and epidemiology of high-risk HPV infections and summarize concepts and performance of available cervical cancer screening tests. An update on recent changes to screening guidelines will be provided.


CME/SAM


PACE

 
Autoantibody Testing in the Diagnosis of Autoimmune Neurological Disorders by Lisa K. Peterson, PhD
Number of Credits: 1.0

Autoimmune neurology is a rapidly evolving field, with additional autoantibodies continually being identified. This presentation will focus on the laboratory’s role in diagnosing and managing autoimmune neurologic disorders, including paraneoplastic neurological syndromes (PNS), autoimmune encephalitis, and autoimmune neuromuscular junction disorders. Also discussed will be methods for detecting autoantibodies in serum and CSF, with an emphasis on their strengths and weaknesses, as well as testing strategies for autoimmune neurologic diseases.


CME/SAM


PACE


Florida

Update on Anticoagulants Monitoring Practice by Kristi J. Smock, MD
Number of Credits: 0.5

The direct oral anticoagulants (DOACs) currently include one direct thrombin inhibitor (dabigatran) and three direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) which have various approvals for treatment and prevention of thromboembolic events, As opposed to more traditional anticoagulants, DOACs do not require routine laboratory monitoring due to predictable pharmacodynamics, pharmacokinetics, and wide therapeutic windows. DOACs have variable effects on routine coagulation tests, such as PT/INR and aPTT, depending on the specific drug, drug concentration in the specimen, patient and specific indication and dose, and assay, including the specific reagent used. Understanding DOAC effects on locally available routine coagulation tests may allow qualitative use of routine tests in emergent clinical situations but these tests do not reliably determine drug concentration. Although quantitative tests for the new drugs exist, they are not widely available, usually do not have turnaround times that would allow use in urgent clinical situations, and none are FDA approved. Aside from the issues with monitoring DOACs, it is also important for physicians and laboratory professionals to know that DOACs can interfere with specialized coagulation testing, such as thrombophilia testing, and that this testing should generally be avoided when DOACs are present.


CME/SAM


PACE

 
Employee Mentoring: Fostering a Culture of Contribution by Jo D Fontenot, MS, MT(ASCP)
Number of Credits: 0.75

This lecture will describe the roles of a mentor and protégé. It will evaluate the responsibilities of each member of the partnership to ensure cross functional development within the organizations. It will describe strategies to use when setting up a successful mentoring program.

 

PACE

 
Diagnostic Errors in (Anatomic) Pathology by Michael Cohen, MD
Number of Credits: 1.0

The aim of this presentation is to familiarize listeners with the relatively recently (9/2015) released IOM (Institute of Medicine) report on diagnostic errors and the importance of cognitive errors.


CME/SAM


PACE


Florida

Role of Clinical Exome Sequencing in Diagnostic Odyssey by Pinar Bayrak-Toydemir, MD, PhD
Number of Credits: 0.5

As next generation sequencing technologies improve in accuracy and cost effectiveness, they will become standard in research and clinical laboratories. This presentation discusses exome sequencing in clinical testing. It will summarize clinical sensitivity of exome sequencing based on age, clinical findings, number of family members sequenced, and type of mutations. Two interesting exome cases will be discussed in details from clinical findings to reporting. There will be also a discussion about incidental/ secondary findings, and American College of Medical Genetics Recommendations.


CME/SAM


PACE

 
The Paris System by Eva M. Wojcik, MD
Number of Credits: 1.5

The Paris System for Reporting Urinary Cytology (TPS) has been developed by international group of members of the American Society of Cytopathology and the International Academy of Cytology to emphasize the goal of detecting High Grade Urothelial Carcinoma (HGUC) while minimizing the emphasis on Low Grade Urothelial Neoplasms (LGUN). Consequently, definition of the characteristics of the intermediate category of atypia aims at decreasing that category into a clinically meaningful one. Criteria for each category have been based on the best available clinical outcomes evidence. The uniqueness of the Paris System for Reporting Urinary Cytology lies in the fact that the system is based on understanding of the pathogenesis of urothelial carcinoma and recognizing two separate pathogenetic pathways; one leading to the development of a low grade urothelial neoplasm and the other leading to the formation of a high grade urothelial carcinoma, which is clinically significant and should be detected by cytology. From its inception, the system became enthusiastically accepted by cytology practitioners who recognized the significance of this more simplistic, but clinically significant, approach to urine cytology. It appears that urine cytology is no longer one of the most frustrating and difficult areas of cytology.


CME/SAM


PACE


Florida

EIN – The Final "Word" in Pre-Malignant Endometrioid Neoplasia by Elke Jarboe, MD
Number of Credits: 1.0

Endometrial intraepithelial neoplasia (EIN) is a monoclonal premalignant endometrial glandular lesion that precedes the development of endometrioid-type endometrial adenocarcinoma. EIN arises through complex interactions involving the sequential accumulation of genetic damage in endometrial glands and the positive selective pressure of unopposed estrogen. EIN is associated with a 45-fold increased risk of developing endometrial adenocarcinoma. In 2015, the American College of Obstetricians and Gynecologists and the Society of Gynecologic Oncology sanctioned EIN as the preferred diagnostic schema (over the WHO 1994 hyperplasia classification system) for diagnosing premalignant endometrial lesions.


CME/SAM


PACE


Florida

Human Microbiome in Health and Disease by David R. Hillyard, MD
Number of Credits: 1.0

Microorganisms have long been known to play an essential role in digestion and gut physiology. The advent of next-generation sequencing (NGS) and advanced informatics has accelerated research in this area, revealing complex signaling networks between microbes and their hosts beginning before birth. The role of the microbiome in health and disease is the focus of research that spans many disciplines, from nutrition and immunology to cardiology and neuroscience.

This presentation will review basic concepts of microbiome science, with a focus on advancements that suggest important causal relationships between the human microbiome and disease.


CME/SAM


PACE


Florida

Topics in Intraoperative Gynecologic Oncology by Mark Dodson, MD
Number of Credits: 1.0

This is a lecture addressing gynecologic tumors and the importance of accurate intraoperative and postoperative pathologic results. We will discuss the nuances of specific pathologic findings that direct our approach to clinical management of the patient.


CME/SAM


PACE


Florida

New Approaches to the Diagnosis of Prosthetic Joint Infection by Robin Patel, MD(CM), FRCP(C), D(ABMM), FIDSA, FACP, F(AAM)
Number of Credits: 1.0

Prosthetic joint infection occurs as a result of the formation of biofilms on the surface of orthopedic implants. The number of prosthetic joint infections is rising; diagnosis of this condition can be challenging. Our group has an over two decade history of performing studies to try to improve the diagnosis of prosthetic joint infection. A decade ago, we described a strategy to sample bacteria growing in biofilms on surfaces of removed joint replacements, an approach that is now a standard means of prosthetic joint infection diagnosis. In addition, this tactic is enabling us to answer a number of fundamental questions about the microbiology and pathogenesis of prosthetic joint infection through multiplex nucleic acid amplification panel, broad-range polymerase chain reaction and deep sequencing studies. Last year, we described an improved method for culturing tissue specimens from around orthopedic implants. We have defined how to interpret results of blood tests (e.g., CRP, ESR) and synovial fluid tests (e.g., cell count, neutrophil differential) for prosthetic joint infection diagnosis. This presentation will provide an overview of the diagnosis of prosthetic joint infection.


CME/SAM


PACE


Florida

Heparin-Induced Thrombocytopenia: The Dark Side of a Common Anticoagulant by George M. Rodgers III, MD, PhD, and Kristi J. Smock, MD
Number of Credits: 1.0

Heparin-induced thrombocytopenia (HIT) is a syndrome of platelet activation, thrombocytopenia, and thrombosis that occurs in 1-5% of patients who receive heparin. HIT is a clinicopathologic diagnosis where laboratory testing plays an essential role. Accurate and timely diagnosis is essential to avoid potentially life- or limb- threatening thrombotic complications. It is also important to avoid HIT over-diagnosis, which is common, and leads to suboptimal patient management. This presentation will emphasize the role of the laboratory in HIT diagnosis. At the conclusion, participants will be able to describe the syndrome, available laboratory testing, and optimal diagnostic algorithms.


CME/SAM


PACE


Florida

Sizing Up Cancer in Cell-Free DNA by Hunter Underhill, MD, PhD
Number of Credits: 1.0

During cell death, DNA that is not contained within a membrane (i.e., cell-free DNA) enters the circulation. Detecting cell-free DNA originating from solid tumors (i.e., circulating tumor DNA, ctDNA), particularly solid tumors that have not metastasized, has proven challenging due to the relatively abundant background of normally occurring cell-free DNA derived from healthy cells. This presentation will discuss the recent discovery that circulating tumor DNA has a distinctly shorter fragment length than normal cell-free DNA derived from healthy cells. The leveraging of this biological phenomenon to improve the non-invasive detection and diagnosis of solid tumors (i.e., the "liquid biopsy"), monitoring tumor recurrence, and evaluating tumor response to therapy will also be considered.


CME/SAM


PACE


Florida

Next-Generation Sequencing for Solid Tumors Diagnostics: Current Practice and New Developments by Larissa V. Furtado, MD
Number of Credits: 1.0

The role of molecular and genomic analysis in the diagnostic work-up of solid tumors continues to expand, with dramatic implications for clinicians, pathologists, and patients. With the recent surge of next-generation sequencing (NGS) adoption into clinical diagnostics laboratories, pathologists are more than ever required to actively participate as consultants on test selection and integrated clinical interpretation. This lecture will provide an overview of current next-generation technologies and their capabilities and indications for use in solid tumor diagnosis and management. These concepts will be reinforced with examples of personalized genomic analysis and management of a variety of solid tumors. Future trends in personalized tumor management will also be covered, including possibilities for testing of emerging specimen types, such as fine-needle aspirates and blood and other bodily fluids, from which trace cancer signals can be detected.


CME/SAM


PACE


Florida

Emerging and Zoonotic Infections by Marc Roger Couturier, PhD, D(ABMM)
Number of Credits: CME/SAM: 1.0 PACE: 1.0 Florida: 1.0

With globalization of food products, pan-global human travel, and changing vector ranges for insects that carry disease, the rise of emerging and/or zoonotic infections has never been more prominent. Many recently emerging pathogens are zoonotic viruses and their emergence in new parts of the world is alarming and a challenge to medicine. Viruses such as Zika virus, chikungunya virus, MERS coronavirus, and ebola will be discussed, and the emerging enteric pathogen, Cyclospora will also be reviewed. A focus on sociopolitical as well as epidemiological factors will be considered for this topic, as both have significant implications in the emergence and persistence of these various pathogens.


CME/SAM


PACE


Florida

How to Develop an Effective Utilization Management Program by Robert Schmidt, MD, PhD, MBA
Number of Credits: 1.0

This presentation will provide practical examples of successful interventions and discuss the following key features of effective utilization management programs: getting started, designing the program, selecting projects, measuring progress, and maintaining momentum.


CME/SAM


PACE


Florida

Helicobacter pylori: Update on Disease, Diagnosis and Discouraging Trends by Marc Roger Couturier, PhD, D(ABMM)
Number of Credits: 1.0

Helicobacter pylori is one of the most common bacterial infections worldwide, with infection rates upwards of 50% of the human population.  While most of these infections are asymptomatic, a significant number of patients will develop severe disease due to this bacterial pathogen, including serious life threatening gastric cancers. The testing strategy for Helicobacter pylori will be reviewed, with particular focus on the non-invasive mechanisms of testing that are central to the clinical pathology laboratory and consistent with guidelines issues by multiple professional organizations. Finally, challenges related to proper test utilization and treatment failures will be discussed.


CME/SAM


PACE


Florida

Is There a Bully in the Room? by Tiffany A. Bradshaw, MLS(ASCP)CM
Number of Credits: 0.5

This lecture will examine how bullying in the workplace might be defined and specific examples of how these behaviors might be displayed. In addition, methods for addressing and dealing with bullying, as well as current legislative and organizational strategies, will be covered.

 

PACE

 
Genomic Microarray in Constitutional and Oncology Settings by Erica Andersen, PhD
Number of Credits: 1.0

Genomic microarray analysis has utility across multiple areas of medicine as a clinical test for both heritable (constitutional) and acquired (oncologic) genetic abnormalities. This presentation will provide an overview of both the technical and interpretive aspects of genomic microarray analysis in order to facilitate better understanding of the clinical utility of this test.


CME/SAM


PACE


Florida

Quantitative Amino Acids Analysis for the Diagnosis and Follow Up of Inborn Errors of Metabolism by Irene De Biase, MD, PhD, FACMG
Number of Credits: 0.75

Inborn errors of metabolism are single gene disorders resulting from defects in metabolic pathways. Individually these disorders are rare, but collectively inborn errors of metabolism account for a significant portion of childhood disability and deaths. Moreover, they are in the differential diagnosis for common clinical emergencies, like neonatal sepsis and seizures. Correctly identifying these conditions is paramount, since prompt specific treatment is, in most cases, life-saving. Excluding a metabolic disorder requires several specific biochemical genetics tests, including the quantitative analysis of physiological amino acids in body fluids. This presentation will review the different methods used to quantify amino acids and amino acid-related compounds, and their use in the diagnosis and follow-up of inborn errors of metabolism.


CME/SAM


PACE

 
Medical and Non-Medical Testosterone and Steroid Hormone Usage by Amanda Ho, MD
Number of Credits: 1.0

Testosterone is a hormone present in both men and women with a variety of effects throughout the body. It’s prescribed by medical professionals for several different conditions and testosterone levels are commonly measured in patients receiving testosterone therapy. There are many different laboratory tests available to measure testosterone; choosing the proper test can be confusing. In addition to the medical usages, testosterone and similar anabolic-androgenic steroids are also used and abused to increase athletic performance or improve appearance. This presentation provides an overview of how testosterone works, how to choose the right laboratory test to monitor testosterone levels, and the similarities and differences between testosterone and anabolic-androgenic steroids.


CME/SAM


PACE


Florida

ELISA Science by The ARUP Institute for Learning
Number of Credits: 1.25

This course describes the Enzyme Linked Immunosorbant Assay (ELISA) testing method used in many analytical tests. Included are descriptions of the testing process and what is being tested. Animations are used to help illustrate what is happening at the molecular level.

 

PACE


Florida

FNA Cytology of the Head and Neck: Diagnostic Approach to Common Cases by Benjamin L. Witt, MD
Number of Credits: 1.0

This lecture will be an overview of FNA cytology of the head and neck using a case-based approach to discuss some of the more common diagnostic dilemmas. The topics that will be emphasized include lymph nodes, cystic neck masses, reactive reparative changes, and salivary gland lesions.


CME/SAM


PACE


Florida

Update in Salivary Gland Pathology by Benjamin L. Witt, MD
Number of Credits: 0.75

The classification of salivary gland neoplasms can be difficult due to the morphologic overlap between tumor types and the variability in patterns that frequent many of the tumors. The goal of this lecture is to focus on a selection of the common tumors of the salivary gland and illustrate their expected morphologic variability. Recommendations for immunohistochemical panels to help navigate certain differential diagnoses will be addressed. A couple of the newer topics in salivary gland pathology will also be discussed. This will include discussion on the recently described entity Mammary Analogue Secretory Carcinoma and the concept of high grade transformation in salivary gland carcinomas.


CME/SAM


PACE

 
Personalized Drug Therapy Is Here! An Update on Genetic Tools and Clinical Decision Support Available to Guide Drug and Dose Selection Today by Gwen McMillin, PhD, DABCC(CC,TC)
Number of Credits: 1.0

A person's response to a drug is dependent on many factors, including genetic variation. Targeted genetic testing can predict adverse drug reactions and therapeutic failure, as well as the need for non-standard dosing of several clinically important drugs. Expert consensus regarding implementing specific drug-gene associations has led to clinical decision support that can guide drug and dose selection based on genetic test results. This webinar will offer examples of how genetic testing can be used to personalize pharmacotherapy decisions.


CME/SAM


PACE


Florida

Diagnostic Trends in Laboratory Evaluation of Antiphospholipid Syndrome by Anne E. Tebo, PhD
Number of Credits: 0.5

Antiphospholipid syndrome (APS) is an autoimmune disease characterized by vascular thrombosis and/or pregnancy-related morbidity accompanied by persistently positive antiphospholipid (aPL) antibodies. Current recommended laboratory tests include immunoassays for detecting IgG and IgM antibodies to cardiolipin (aCL), and beta-2 glycoprotein I (anti-β2GPI) as well as coagulation-based assays for lupus anticoagulant activities. It is increasingly recognized that a subset of patients with classical features of APS do test negative for the recommended criteria aPL tests. While APS experts acknowledge that such patients may have clinical features that are not of an autoimmune etiology, ‘seronegativity’ for criteria autoantibodies may also be due in part to the absence of harmonization and/or standardization of current aPL antibody assays. Alternatively, patients ‘seronegative’ for the recommended tests may have aPL antibodies that target other antigens involved in the pathogenesis of APS with possible relevance for risk assessment and treatment. This presentation will focus on current and emerging aPL antibodies and the evolving concepts for their use in the evaluation and management of APS.


CME/SAM


PACE

 
Laboratory Diagnosis of Hemoglobinopathies and Thalassemia by Archana Mishra Agarwal, MD
Number of Credits: 1.0

Hemoglobinopathies and thalassemias are among the most common genetic diseases, with 7 percent of the world’s population carrying a hemoglobin mutation. Due to relatively recent migration, North American countries are now home to a large number of patients with thalassemia. Among these disorders, sickle cell syndromes and thalassemias constitute major public health problems.

Most laboratories use a combination of high-performance liquid chromatography (HPLC), capillary electrophoresis, molecular analysis, and mass spectrometry to diagnose thalassemias. Definite identification of hemoglobinopathies can be achieved by a stepwise alogrithmic approach that includes a detailed clinical history, HPLC, and molecular analysis. This presentation will review the pathophysiology, pertinent clinical and laboratory findings, and recent advances in the field.


CME/SAM


PACE


Florida

Pharmacogenetics of CYP-mediated drug metabolism by Gwendolyn A. McMillin, PhD
Number of Credits: 0.5

Cytochrome P450 (CYP) enzymes are responsible for metabolism of approximately 75% of all drugs. Variation in CYP genes that code for CYP enzymes can predict how a person will metabolize specific drugs. This presentation describes pharmacogenetics of CYPs and models for clinical implementation.


CME/SAM


PACE

 
Therapeutic drug monitoring (TDM) of thiopurine drugs by Kamisha Johnson-Davis, PhD, DABCC
Number of Credits: 0.5

Thiopurine drugs are prescribed to treat patients with acute lymphoblastic leukemia, autoimmune diseases and inflammatory bowel disease. Thiopurine drugs must be metabolized to pharmacologically active metabolites in order to exert its effects. The amount of active metabolites is regulated by the enzyme, thiopurine methyltransferase, which functions to inactivate about 90% of the drug dose to balance the formation of active metabolites. Individuals with low TPMT activity are unable to inactivate the drug methylation and these individuals are at risk for bone marrow toxicity, if they receive standard dose therapy. Therefore, TPMT activity should be assessed prior thiopurine drug administration.


CME/SAM


PACE

 
Metagenomics for Universal Pathogen Detection by Robert Schlaberg, MD, Dr Med, MPH
Number of Credits: 0.5

Metagenomics, the genomic analysis of a population of microorganisms, makes possible the profiling of microbial communities in the environment and the human body at unprecedented depth and breadth. Its rapidly expanding use is revolutionizing our understanding of microbial diversity in natural and man-made environments and is linking microbial community profiles with health and disease. In addition, recent progress in rapid and accurate data analysis has also demonstrated promise of metagenomics-based approaches for universal pathogen detection in routine patient samples. This lecture discusses approaches, promises, and challenges for the use of metagenomics-based tests in diagnostic laboratories.


CME/SAM


PACE

 
Introduction to Antibody Identification by Justin R. Rhees, MS, MLS(ASCP)CM, SBB CM
Number of Credits: 1.0

Several effective approaches to antibody identification in the routine blood bank exist. This presentation explains a conservative approach to antibody identification and several demonstrations of ruling out, choosing appropriate selected cells, and completing antibody workups are given.

 

PACE


Florida

Shiga-toxigenic E. coli: A Fully Emerged, Still-Underappreciated Pathogen by Marc Roger Couturier, PhD, D(ABMM)
Number of Credits: 1.0

Shiga-toxigenic E. coli (STEC) is an enteric pathogen associated with several foodborne infections throughout the world every year. The major virulence determinant that defines STEC is the Shiga-like toxin, which is capable of transmission between various gram-negative organisms. STEC causes significant morbidity during acute outbreaks and can cause mortality associated with the development of hemolytic uremic syndrome. Until recently, testing for STEC in the clinical laboratory was inadequate, relying solely on selective, serogroup-biased culture methods. Recent advancements have been made that allow for toxin detection or molecular detection of toxin genes from stool specimens, removing the culture-bias problem. With these improvements in screening, the cases of STEC reported have increased significantly, revealing a pathogen that may have eluded the laboratory for decades. The 2011 STEC outbreak in Germany will be discussed in detail as an example of the emerging nature of this enigmatic pathogen.

 

PACE


Florida

Building a Laboratory Utilization Management Program: A Roadmap for Success by Suzanne Carasso, MBA, MT (ASCP)
Number of Credits: 1.0

By following a step-by-step roadmap with proven success, learn how to establish an effective laboratory utilization management program. You will see how to leverage lab data, establish the right governance structure, create a formulary or employ other strategies, implement system changes to alter physician ordering behavior and measure your success. Hear how to avoid potential pitfalls and harness best practices to start reducing costs and improving care through appropriate test utilization.

Key elements of the roadmap include:

  • Analytics
  • Governance
  • Formulary and other UM strategies
  • Implementation
  • Maintenance

CME/SAM


PACE


Florida

Clinical Next-Gen Sequencing for Solid Tumors: What, How, Why, and When? by Christopher Corless, MD, PhD
Number of Credits: 1.0

This presentation provides an overview of the role of next-generation sequencing technologies in the molecular subtyping of solid tumors. Points of emphasis include approaches to maximizing genomic information from very small FFPE tumor samples, the spectrum of mutations and other genetic alterations that are important in non-small cell lung cancer, and the challenges of interpreting rare sequence variants.


CME/SAM


PACE


Florida

Circulating Tumor DNA: Disruptive Technology in Medicine by Mary Bronner, MD
Number of Credits: 1.0

The phenomenon of tumors shedding DNA into the blood has opened exciting opportunities in cancer diagnosis, monitoring, and treatment. Circulating tumor DNA (ctDNA) in blood plasma can be detected by multiple new technologies. ctDNA testing is projected to transform and disrupt the disciplines of molecular pathology and clinical oncology by: replacing large sectors of the >$20 billion annual U.S. cancer imaging industry for tumor diagnosis and recurrence; detecting chemotherapeutic tumor-resistance mutations as they develop in patients; replacing highly invasive tissue biopsy and surgery to diagnose and direct recurrent tumor therapy; revolutionizing tumor sampling via diffuse blood perfusion, which may theoretically circumvent the major biologic problem of tumor heterogeneity; and possibly improving cancer screening.


CME/SAM


PACE


Florida

Hereditary Breast and Ovarian Cancer and Genetic Testing by Rong Mao, MD, and Gwendolyn A. McMillin, PhD
Number of Credits: 0.5

In this video lecture Dr. Mao will explain hereditary breast cancer, testing and what can be done if a risk is detected. Dr. McMillin with discuss germline pharmacogenetic testing and how this line of testing can assist with the treatment of breast cancer.


CME/SAM


PACE

 
Multiplex/molecular testing for gastrointestinal infections by Marc Roger Couturier, PhD, D(ABMM)
Number of Credits: 1.0

The field of molecular diagnostics for gastrointestinal infections has exploded in the past two years. Multiple platforms have been cleared by the FDA for clinical use and more continue to come to market. Evolving issues concerning utilization and implementaion of these new technologies will be discussed in detail.


CME/SAM


PACE


Florida

The Squeeze on Molecular Pathology by Aaron Bossler, MD PhD
Number of Credits: 1.0

This presentation will highlight two issues impacting the delivery of molecular pathology procedures: 1. Coding and reimbursement of molecular pathology and genomic sequence procedures and 2. Regulation of laboratory developed tests by the FDA as indicated in the 2014 draft guidance that is pending implementation. Details regarding the Association for Molecular Pathology project to determine costs and value of performing next generation sequencing based testing will be provided. Discussion of alternative options to the FDA draft guidance will also be presented.


CME/SAM


PACE


Florida

Introduction to the Rhesus Blood Group by Justin R. Rhees, MS, MLS(ASCP)CM, SBBCM
Number of Credits: 1.0

The Rh blood group system is one of the largest and most polymorphic. This presentation describes several Rh antigens and antibodies of clinical significance, Weak D phenotypes, and rare phenotypes that result from deletions and gene mutations. In addition, different nomenclature systems are explained.

 

PACE


Florida

Next-Generation Sequencing of Hematologic Neoplasms by Todd Kelley, MD
Number of Credits: 1.0

This video lecture will focus on next-generation sequencing (NGS)-based tests in hematologic neoplasms, particularly the clinical utility of this technology and how it is revolutionizing the management of patients with hematologic neoplasms. The design and development of NGS tests, including a basic overview of a test pipeline with both laboratory and informatics components, will also be discussed.


CME/SAM


PACE


Florida

Molecular testing in GI cancer by Wade Samowitz, MD
Number of Credits: 1.0

Molecular testing in gastrointestinal cancers has emerged as an exciting new field in pathology. In the gastrointestinal tract, this started with the work-up of Lynch syndrome. This work-up involves two major steps: determining whether a colorectal cancer is mismatch repair deficient, either by microsatellite instability or immunohistochemistry (IHC) for mismatch repair proteins, and then determining whether a mismatch repair deficient tumor is sporadic or Lynch syndrome-associated. Clues that a mismatch repair deficient tumor is sporadic are an IHC profile of loss of MLH1 and PMS2 combined with a BRAF V600E mutation and/or MLH1 promoter methylation. The second major application for molecular diagnostics in colorectal cancer involves determining the potential utility of cetuximab therapy directed against the EGFR receptor in advanced disease. In this case alterations in genes downstream of EGFR, including KRAS, NRAS, BRAF, PIK3CA and PTEN, render such treatment ineffective, and therefore evaluation of these downstream genes is important to insure that only patients who may benefit from a relatively toxic and expensive drug are treated. More molecular targets will undoubtedly be discovered in the future, greatly increasing the number of molecular diagnostic tests. This will make next generation sequencing, or massively parallel sequencing, a technique in which numerous genes are evaluated simultaneously, an increasingly attractive alternative to single gene tests, especially as the cost of next generation sequencing continues to decrease.


CME/SAM


PACE


Florida

Laboratory Testing to Support Pain Management: Methods and Case Studies by Frederick Strathmann, PhD
Number of Credits: 1.0

The focus of this presentation is on understanding the laboratory's role drug testing in the context of therapeutic drug monitoring, pain management, and drug abuse. Testing methods and principles including immunoassays and various mass spectrometry techniques are highlighted and comparisons are made between urine and serum regarding detection times and drug metabolite targets. In the context of several case studies, drug metabolism is reviewed and the broader concept of screening vs. confirmation testing is discussed.


CME/SAM


PACE


Florida

The Evolving Classification of Soft Tissue Tumors by Christopher, D.M. Fletcher, MD, FRCPath
Number of Credits: 1.0

With the advent of the new format for WHO tumor classifications, there have been major changes in each of the most recent volumes (2002 and 2013) concerning soft tissue neoplasms. Perhaps foremost has been the disappearance of "malignant fibrous histiocytoma" and "hemangiopericytoma." In 2013, the category of undifferentiated sarcomas was introduced, and a large amount of new genetic data across many tumor types was incorporated. Even since the completion of the latest volume (which was published almost a year after the consensus meeting at which the content was finalized), there have been important new findings in solitary fibrous tumor, a subset of rhabdomyosarcomas and among round cell sarcomas. Increasing genetic overlap among seemingly distinct tumour types is emerging and, in the future, the relative importance of phenotype vs. genotype will need to be determined. There also remain opportunities to address significant nomenclatural problems.


CME/SAM


PACE


Florida

Cost-Effectiveness Analysis of Laboratory Tests by Robert Schmidt, MD, PhD, MBA
Number of Credits: 1.0

Laboratories are under intense pressure to increase value. Cost-effectiveness analysis (CEA) can help labs increase value by identifying optimum testing scenarios. This webinar explains important concepts such as cost-perspectives, methods for estimating costs, estimating outcomes, evaluating outcomes, and evaluating uncertainty in model outputs. At the end of this lecture, viewers will understand the different types of frameworks and analyses that are used in cost-effectiveness analysis.


CME/SAM


PACE


Florida

Risk Mitigation in Breast Predictive Factor Testing by Elizabeth H. Hammond, MD, FCAP
Number of Credits: 0.5

In this course, the risks to laboratories and pathologists inherent in biomarker testing are described along with a process to identify and mitigate the risks of testing.


CME/SAM


PACE

 
Breast Predictive Factor Update by Elizabeth H. Hammond, MD, FCAP
Number of Credits: 0.5

American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP) produced collaborative guidelines for HER2 and ER/PgR Testing in Breast Cancer in 2007 and 2011 respectively The HER2 Guideline has recently been updated. This course summarizes the content of these guidelines and updates the recommendations for HER2 included in the 2013 publication.


CME/SAM


PACE

 
Atypical Lesions: To Excise or Not To Excise? by H. Evin Gulbahce, MD
Number of Credits: 1.0

This lecture discusses challenges in diagnosing atypical breast lesions on core biopsies including flat epithelial atypia and lobular neoplasia. In the lecture, we will also review the classic and most current literature in helping guide management of these patients (i.e. close follow up versus referring the patient for surgical excision).


CME/SAM


PACE


Florida

Molecular Testing in Breast Cancer: An Oncologist’s Perspective by Adam Cohen, MD
Number of Credits: 1.0

Medical oncologists try to tailor treatment to each individual woman’s cancer’s biologic and clinical features. These features determine the risk of relapse and drug sensitivity for early breast cancer and the prognosis and treatment options for late breast cancer. Gene expression tests, including OncotypeDx, MammaPrint, Prosigna, and BCI, attempt to measure factors such as ER activation and proliferation to provide estimates of prognosis and chemotherapy sensitivity in early ER-positive breast cancer. They each provide similar information, and clinical factors such as age, tumor size, and grade retain independent prognostic value. In metastatic breast cancer, circulating tumor cells (CTCs) are prognostic and can be used to detect mutation, but cannot be used currently to guide choice of chemotherapy. Ongoing trials are assessing the use of therapy based on mutations in CTCs or in tumor themselves.

Originally presented on February 09, 2015 in Park City, Utah.


CME/SAM


PACE


Florida

Updates in Margin Status and Lymph Node Dissection by Leigh Neumayer, MD, MS, FACS
Number of Credits: 1.0

Recently published guidelines for margin width in breast conserving therapy are reviewed along with the most up to date recommendations for the management of the axilla in breast cancer. The importance of a team approach to the patient with breast cancer is also emphasized.

Originally presented on March 10, 2015 in Salt Lake City, Utah.


CME/SAM


PACE


Florida

The Changing Landscape of Hepatitis C Testing and Therapy by David R. Hillyard, MD
Number of Credits: 1.0

The discovery, diagnosis, and treatment of the hepatitis C virus (HCV) rank as one of modern medicine’s great accomplishments. At each stage of the HCV revolution, laboratory testing has been key to foundational research, identification of chronically infected patients, and rational guidance of evolving therapies. Recent initiatives for comprehensive screening and the availability of new well-tolerated, highly effective therapies have galvanized the public’s attention as never before.

This video lecture will review the evolving role of laboratory testing in the diagnosis and management of chronic HCV infection, focusing on current guidelines and test resources. It will also address expected public health outcomes and issues in this era of the HCV cure.


CME/SAM


PACE


Florida

Lysosomal Acid Lipase Deficiency: An Under-diagnosed Cause of Liver Dysfunction by Irene De Biase, MD, PhD
Number of Credits: 0.5

Lysosomal acid lipase deficiency is characterized by the accumulation of cholesteryl esters and triglycerides. Patients present with gastrointestinal symptoms, liver dysfunction, and dyslipidemia, progressing to premature atherosclerosis and cardiovascular disease. Due to its clinical variability and the similarity with other, more common disorders, lysosomal acid lipase deficiency is under-recognized. Identifying this disease by using specific diagnostic testing is critical since enzyme replacement therapy (ERT) is available and very effective.

Originally presented on June 25, 2015 in Salt Lake City, Utah.


CME/SAM


PACE

 
Spindle Cell Lesions of the Breast by Erinn Downs-Kelly, DO, MS
Number of Credits: 1.0

The workup of spindle cell lesions of the breast requires the judicious use of immunohistochemical stains to arrive at the correct diagnosis, especially on core-needle biopsy. The entities, both benign and malignant, that compose the spindle cell lesions of the breast will be discussed.

Originally presented on February 09, 2015, in Park City, Utah.


CME/SAM


PACE


Florida

Understanding Lymphoma from a Lab Perspective by Mohamed E. Salama, MD
Number of Credits: 0.75

In this presentation we summarize the pathologic classification of Lymphomas according to the 2008 WHO classification. We focus on the aspect for the classification that is related to laboratory such as workflow and ancillary testing including flow cytometry utilized in the diagnosis. We compare and contrast the natural history, clinical features, staging and treatment approach of common NHL subtypes as well as the relevant therapeutic implications for reaching to correct diagnosis.

Originally presented on May 26, 2015 in Salt Lake City, Utah.


CME/SAM


PACE

 
Hereditary Colonic Polyposis Syndromes by Kory Jasperson, MS, CGC
Number of Credits: 1.0

The colonic polyposis syndromes comprise a heterogeneous group of conditions with varying cancer risks, polyp types, non-malignant findings, and inheritance patterns. Screening and prevention recommendations vary among these syndromes and therefore an accurate diagnosis is critical. This presentation will summarize the characteristic features and red flags of certain hereditary polyposis syndromes.

Originally presented on February 12, 2015 in Park City, Utah.


CME/SAM


PACE


Florida

The Lewis System by Justin R. Rhees, MS, MLS(ASCP)CM SBB CM
Number of Credits: 0.5

The Lewis system is unique among blood group systems in that the antigens are not manufactured within the erythrocyte, nor do they form an integral part of the cytoskeletal membrane. Rather, they are synthesized by tissues, secreted into blood and body fluids, and adsorb onto the red blood cell. While antibodies against antigens in this system are fairly commonly encountered, they are generally not considered to be clinically significant in transfusion. In vitro and in vivo hemolysis are rare but have been reported. Because Lewis phenotype expression is based upon the interaction of several genes, and because the phenotype expression can be transient, the Lewis system is a fascinating system to learn about.

Originally presented on August 07, 2015 in Salt Lake City, Utah.

 

PACE

 
Diagnostic Approach to Anemia by Archana Mishra Agarwal, MD
Number of Credits: CME/SAM: 1.25 PACE: 1 Florida: 1.3

The understanding of anemias is very important as clinicians attempt to provide high quality medical care to their patients. The medical laboratory scientist must also understand anemias to provide the needed information to physicians. This lecture will address the basics of the classification of anemias and tools used in the medical laboratory to assess a patient’s blood health or presence of anemia.

 

PACE


Florida

Hematology M+Ms: Morphology and Mystery (Case Studies) by Karen A. Brown, MS, MLS (ASCP)CM
Number of Credits: 1.0

Hematology instrumentation has advanced to now routinely include at least a five-part differential and, in some laboratories, automated cell image analysis. Yet, a manual examination of the blood smear is still an essential procedure that provides valuable diagnostic information. This session will use case studies to define important morphologic variations and physiologic processes in selected disease conditions.

Originally presented on July 15, 2015 in Salt Lake City, Utah.

 

PACE


Florida

The Illusion of Quality: A Discussion of Roadblocks to Laboratory Quality and Case Studies of How to Make Things Better by Frederick G. Strathmann, PhD, DABCC (CC, TC)
Number of Credits: 1.0

The purpose of this presentation is to emphasize the need for every laboratory to continuously review its quality processes. The recent changes surrounding Equivocal QC practices provide an opportunity for laboratories to ensure minimum requirements are met and a chance to move towards raising the bar internally for quality requirements. Practical and real-world examples of how to prepare, implement, and measure the impact of changing quality will be presented and discussed.

Originally presented on June 25, 2015 in Salt Lake City, Utah.


CME/SAM


PACE


Florida

Laboratory Formularies: Improving Care, Reducing Costs by Brian R. Jackson, MD, MS
Number of Credits: 0.5

Laboratory formularies are an emerging tool for promoting effective use of the clinical laboratory. This presentation covers the key considerations for developing, applying, and managing a lab formulary: governance, process, evidence base, and analytics. In the end, a formulary is not so much a product as it is an interconnected system for managing and influencing diagnostic practices.

Originally presented on April 17, 2015 in Salt Lake City, Utah.


CME/SAM


PACE

 
Identifying the Pregnant Patient: There's More to Know than 'Yes' or 'No' by David G. Grenache, PhD
Number of Credits: 1.0

Human chorionic gonadotropin (hCG) is used as a biomarker to determine a woman’s pregnancy status. The detection of hCG is commonly done by the use of qualitative hCG tests using urine or serum. While both sample types can be used, urine is often preferred due to its ability to be analyzed at the point-of-care. Urine hCG testing is plagued by several limitations yet these are often not appreciated by clinical care providers and laboratorians. This presentation will describe the limitations of qualitative urine and serum hCG tests and explain the causes of erroneous results. It will also describe the effect that qualitative hCG tests have on turnaround time and patient length of stay.


CME/SAM


PACE


Florida

The Value of the Laboratory: Invest or Outsource? by Suzanne Carasso, MBA, MT (ASCP)
Number of Credits: 1.0

The impact of national healthcare reform, is putting pressure on the healthcare industry to navigate reductions in reimbursement, implement cost-cutting initiatives and improve patient outcomes and quality of life. Changing the way healthcare is delivered and paid for is the new imperative.

Laboratories, now more than ever before, have a unique opportunity to substantially impact both short and long term sustainability of healthcare organizations. However, labs that continue to just produce lab test results will be viewed as a commodity and will likely be outsourced or sold. Some organizations are selling laboratory and outreach operations to private equity firms, joint venture capitalists or national laboratories in exchange for an immediate and significant infusion of cash. It follows that laboratories failing to demonstrate value to the organization face an uncertain future.

This presentation will inform attendees of the industry trends that are influencing these decisions, the risks laboratories face and what labs can do to demonstrate value in tangible ways.

Originally presented on April 30, 2015 in Salt Lake City, Utah.


CME/SAM


PACE


Florida

Testing a Test: Beyond Sensitivity and Specificity by Robert Schmidt, MD, PhD, MBA
Number of Credits: 1.0

In this lecture, Dr. Schmidt covers performance evaluation of diagnostic tests. Traditional performance measures such as sensitivity, specificity and ROC curves are reviewed. Reasons for differences in diagnostic studies are examined including real differences, threshold effects, sources of bias, and random variation. Shortcomings of the traditional approaches to test evaluation are also discussed and alternative approaches such as diagnostic research (vs test research), clinical trial evaluation, and cost-effectiveness evaluation are presented.

Originally presented January 29, 2015 in Salt Lake City, Utah.


CME/SAM


PACE


Florida

Non-invasive Assessment of Liver Fibrosis by Patricia R. Slev, PhD
Number of Credits: 1.0

Chronic liver disease due to a variety of etiologies is a leading cause of morbidity and mortality in the US. Regardless of etiology, assessing the stage of liver disease is critical for treatment decisions, prognosis and general medical management. The gold standard for assessing liver fibrosis is a biopsy. However, biopsies are invasive, expensive and can be accompanied by a number of complications. For these reasons, many non-invasive markers (NIMs) have been developed and are increasingly used in clinical practice. This presentation will review non-invasive approaches for assessing liver fibrosis, with an emphasis on surrogate serum biomarkers, including Fibrosure and Fibrometer.


CME/SAM


PACE


Florida

Diagnostic Error & Laboratory Testing by Mark L. Graber, MD, FACP
Number of Credits: 1.0

Diagnostic error is a major patient safety concern, causing substantial harm and unnecessary medial costs. In every large organization, cases related to diagnostic error make up the largest fraction of filed claims and suits. Although the error rate is not being measured in any setting, it is estimated that 1 in 10 diagnoses is wrong, significantly delayed, or missed altogether. The root causes of diagnostic error include many system-based factors (eg breakdowns in communication, coordinating care, having expertise available when needed, supervision of trainees, etc) as well as cognitive shortcomings. The cognitive errors mostly derive from failures to synthesize the available evidence and inappropriate trust of intuition. Errors related to diagnostic testing are common, and include mistakes by the patient’s doctor (not knowing the best test to order or how to interpret it) as well as problems performing and interpreting the test results by the clinical lab or the Radiology department staff. Many interventions to reduce diagnostic error have been proposed, although few have been rigorously evaluated in clinical practice.

Originally presented on March 19, 2015 in Salt Lake City, Utah.


CME/SAM


PACE


Florida

Financial Modeling for Laboratory Decision Making by Robert Schmidt, MD, PhD, MBA, and Suzanne Carasso, MBA, MT (ASCP)
Number of Credits: 1.0

Laboratory personnel are periodically confronted with complex decisions, such as opting to buy versus lease, adding a new test to the menu, or bringing a reference test in-house. These decisions are generally made with simplistic models that do not adequately capture risk, incorporate alternative courses of action, or allow for sequential decisions that evolve over time. As a result, decision makers often obtain suboptimal results.

This lecture will present cutting-edge techniques that incorporate risk, facilitate the comparison of multiple alternatives, and provide insight into common laboratory decisions.

Participants will learn how to build financial models utilizing Microsoft Excel and Palisade Decision Tools, a popular add-in; how to use decision trees and simulation models; and how to apply these techniques to common laboratory problems.

Originally presented on March 19, 2015 in Salt Lake City, Utah.


CME/SAM


PACE


Florida

The Delta Check in Action: Causes and Consequences of Discrepant Laboratory Results by Joely A. Straseski, PhD, MS, MT(ASCP), DABCC
Number of Credits: 1.0

Discrepant results are often identified by delta check alerts. Delta checks compare current laboratory results to previous results; if the difference between the two values exceeds predetermined biological limits (within a predetermined length of time), a technologist is alerted and the discrepancy can be investigated further. Causes of discrepant laboratory results include both preanalytical and analytical issues, as well as true biological changes occurring within the patient.

Many preanalytical issues cannot be detected by traditional QC methods, leading to the possible reporting of erroneous laboratory results. The wrong result compromises patient care by leading to inappropriate diagnoses or treatment. Delta check alerts provide an additional means to identify these types of problems, in addition to alerting health care providers to true changes in their patient’s condition.

Originally presented on February 12, 2015 in Salt Lake City, Utah.


CME/SAM


PACE


Florida

Laboratory Results - Beyond Patient Testing by Cheryl Vincent, MBA
Number of Credits: 1.0

Clinical Laboratory Scientists are trained to perform laboratory tests and to troubleshoot and validate the results of those tests which contribute to a patient’s medical diagnosis. During this presentation, we will compare the steps involved in pre-analytical, analytical, and post-analytical laboratory testing to the steps involved in pre-analytical, analytical, and post-analytical phases of developing leaders in the clinical laboratory.

 

PACE


Florida

Blood Bank vs Piggy Bank: Keys to Harmonizing Margin and Mission by Kent Gordon, CPA, MAcc
Number of Credits: 1.0

Tired of fighting with the finance department to get the resources you need to carry out your mission? Ever feel that your CFO is from a different planet and that you just can’t communicate? Do financial concerns kill creativity and stifle progress in your organization? Where is the peace? Where is the love?

This lecture will give you practical tips and tools to help your organization balance operational and financial considerations. First, this course unlocks the mysterious world of accounting . . . revealing the core principles, objectives, and concepts of this centuries-old art. Next, we tackle the sometimes thorny subject of “Margin” verses “Mission” providing some useful prospective on this important topic. Next, we shatter the language barrier, giving you simple terms and lingo to facilitate financial communications. Soon you’ll be fluent in the latest accounting jargon. Finally, we conclude with some take-home financial analysis tools that will have your finance people saying: “Wow! – How’d you get so darn smart?!!!”

Originally presented on September 23, 2014 in Salt Lake City, Utah.

 

PACE


Florida

Are You a Customer Service “Have” or “Have Not”? by Cherie V. Petersen, BA
Number of Credits: 1.0

This shouldn’t be shocking news to most healthcare professionals, but customer service IS a critical function of quality patient care. However, when we as laboratorians think about customer service activities and how that translates into patient care, we tend to think it’s just about what occurs in the literal presence of patients. So, here’s what may be news to some, the patient experience isn’t just about what we do when we’re in their physical presence, but also what we do as we interact with everyone who is in any way associated with their care. Therefore, we must make every effort to be engaged in skilled customer service activities with everyone, at all times. Now, the question may arise, what ARE the necessary skills and activities for providing great customer service (i.e., quality patient care) and how well do YOU execute them? This session will provide an opportunity for self-assessment utilizing a customer service skills preferred profile and an interactive discussion regarding the do’s and don’ts for outstanding customer service.

Originally presented on September 10, 2014 in Salt Lake City, Utah.

 

PACE


Florida

Designing for Improvement by Bonnie Messinger, CPHQ, CMQ/OE (ASQ), Six Sigma Black Belt
Number of Credits: 0.75

Our traditional response to complex problems is to find and eliminate the human behaviors that we think are responsible for errors, and are perplexed when the error we thought we eradicated occurs again and again. We ignore the fact that 95% of process performance is attributable to the design of the work and the system in which the work resides and only 5% to the human component. The importance of creative design in the laboratory is often overlooked and its potential is underutilized. In this session we will discover how to design a work environment where error is, if not impossible, at least very difficult. Using innovative problem solving principles and techniques, we will open the door to organizational excellence by design.

Originally presented on August 12, 2014 in Salt Lake City, Utah.

 

PACE

 
Review of Malaria and Plasmodium Species by DeVon C Hale, MD
Number of Credits: 1.0

This is a basic overview of the disease malaria and the causative agents, Plasmodium species. The life cycles of the parasites and their differentiating characteristics in the human host are discussed, for Plasmodium falciparum. P. ovale, P. vivax, P. malariae. Case studies demonstrate the disease states caused by each species.

Originally presented March, 2014 in Salt Lake City, Utah.

 

PACE


Florida

Phlebotomy Ps and Qs: Problems and Quandaries in Specimen Collection by Karen A. Brown, MS, MLS (ASCP)CM
Number of Credits: 1.0

Phlebotomists routinely encounter dangerous conditions, problem patients, and other issues during blood collection. This session will suggest techniques that can help you avoid or safely manage these difficulties. Areas to be discussed include:

  • risks associated with venous blood collection, such as improper vein selection and needlestick exposure
  • unusual patient situations that impact phlebotomy practice, including the cancer and bariatric patient
  • communication barriers and methods to improve patient interactions, like developing good listening skills and effective communication approaches with the elderly

Designed for phlebotomists and phlebotomy students who have comprehension of the basics of the venipuncture technique, this session will enhance your skills, build your knowledge base, and help you deliver the highest quality in patient care.

Originally presented May 06, 2014 in Salt Lake City, Utah.

 

PACE


Florida

Reporting Laboratory Errors Without Fear by Lucinda Manning, BA, MT(ASCP), RN
Number of Credits: 1.0



Originally presented February 10, 2014 in Salt Lake City, Utah.

 

PACE


Florida

Diagnosing Specimen Collection Issues by Ken Curtis, BS PBT(ASCP)
Number of Credits: 1.0

Errors in specimen collection result in inaccurate results. This presentation focuses on identifying specimen collection issues and strategies for preventing them. We will discuss common errors in patient identification, phlebotomy techniques, and specimen labeling. We will also discuss identifying collection issues via pre-analytical processes, training for accuracy in collection, and monitoring improvement.

Originally presented November 05, 2013 in Salt Lake City, Utah.

 

PACE


Florida

Test Utilization: Are You Driving the Bus, Chased by the Bus, or Under It? by Debbi Tiffany MSED, MLS(ASCP)CM SC CM SLS CM
Number of Credits: 0.75

This presentation provides an examination of how one laboratory reviews their test ordering patterns with information readily at hand while leveraging expert assistance to improve test utilization.

Originally presented January 16, 2014 in Salt Lake City, Utah.

 

PACE

 
The Human Side of Change Management by Cheryl Vincent, MBA
Number of Credits: 1.0

When we bring up the topic of change, we often think of it as a negative. But why? We’re not opposed to changing a hairstyle, the color of our hair, changing cars, or even changing jobs. Now cell phone contracts are starting to lighten up so we can have a new cell phone almost every six months. There has been a lot of information written about the logical steps to change, but what about the human side of change? Cheryl Vincent will discuss the steps to change but also add a human dimension to the concept of Change Management.

Originally presented December 13, 2013 in Salt Lake City, Utah.

 

PACE


Florida

When Professionals Meet: Bridging the Gap Between the Laboratory and Nursing by Lucinda Manning, BA, MT(ASCP), RN
Number of Credits: 1.0

Ms. Manning will give a comparison of the differences in learning in the laboratory and nursing professions. She will share personal examples of the struggles each profession has in understanding each other. She will also discuss practical ways to bridge the gaps in understanding between the two professions. Ms. Manning encourages the audience to be interactive and to share problems as well as best practices and successes in bridging the gap between these two professions.

Originally presented May 09, 2013 in Salt Lake City, Utah.

 

PACE


Florida

Error Proofing the Laboratory by Bonnie Messinger, CPHQ, CMQ/OE (ASQ), Six Sigma Black Belt
Number of Credits: 1.0

Eradicating error in healthcare may seem like a Sisyphean task, yet legislators, regulators and the public in general expect error-free work from medical professionals. How to work without error is the subject of countless lectures, papers and studies, encompassing every discipline from manufacturing to service. The Toyota Production System of quality manufacturing uses the term “poke-yoke” (mistake-proofing) to describe the process of eliminating production defects. “Error-Proofing in Healthcare” will distill and discuss the essential elements of “poke-yoke”, starting with defining and exploring the types of error most often encountered in the provision of medical care. Proven improvement tools and techniques for ensuring quality outputs will be presented with practical applications to place the error-proofing strategy in the context of the laboratory.

Originally presented August 12, 2013 in Salt Lake City, Utah.

 

PACE


Florida

***The archived video lectures listed below no longer provide
continuing education credit
since their CE certification has expired.***